Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Top-line results from its Dosing Validation and Dosing Flexibility studies of LPCN 1021
 Monday, June 19, 2017
 5:00pm EDT